Recent Updates
Recently added Catalysts

Varenicline

Phase 3

Smoking Cessation | Small molecule | Other |Harvard Bioscience, Inc.|Last Updated: Nov 3, 2022

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedACTIVE_CONTROLLEDDMC
Total Trials1
Total Enrollment352
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT04015414Varenicline Versus Cytisine for Smoking Cessation in Primary Care SettingPHASE3 COMPLETED 352Jul 14, 2020Nov 1, 2022Nov 3, 20222 Croatia, Slovenia
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Seven day abstinence from tobacco
12-weeks following target quit date

Proportion of patients in the varenicline and cytisine groups who self-report seven-day abstinence from tobacco.

Secondary Endpoints
Seven day abstinence from tobacco country and practice
4-weeks following target quit date
Seven day abstinence from tobacco
8-weeks following target quit date
Continuous smoking cessation
4, 8, 12, and 24 weeks following target quit date
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingSINGLE
ModelPARALLEL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
Varenicline (Champix)ACTIVE_COMPARATORVarenicline treatment will start one week prior to the patient's target quit date at 0.5 mg/day for days 1-3, 0.5 mg twice daily for days 4-7. On the target quit date (day 8), the dose will be increased to 1 mg twice daily and maintained for day 8-week 12. Patients will receive weekly calls during the first 4 weeks and at weeks 8, 12, and 24 to inquire about medication adherence and smoking status, motivate the patient to take the medication, encourage them not to smoke, and ask about possible side effects or other issues.
Cytisine (Tabex)ACTIVE_COMPARATORPatients will be asked to reduce their smoking during the first 4 days of treatment with aim to quit on the 5th day (target quit date). Cytisine treatment will follow standard manufacturer's dosing protocol of one tablet every 2 hours through the waking day (up to 6 tablets per day) for days 1-3, one tablet every 2.5 hours (up to 5 tablets per day) for days 4-12, one tablet every 3 hours (up to 4 tablets per day) for days 13-16, one tablet every 4-5 hours (3 tablets per day) for days 17-20, and one tablet every 6 hours (2 tablets per day) for days 21-25.
Interventions
NameTypeDescription
VareniclineDRUG191 patients will receive varenicline for 12 weeks and regular phone calls with brief counseling Tabex: 188 patients will receive cytisine for 25 days and regular phone calls with brief counseling
CytisineDRUG185 patients will receive cytisine for 25 days and regular phone calls with brief counseling
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — N/A
SexALL
Healthy VolunteersNo
Study Sites2

Inclusion Criteria: * Receive care in one of forty family medicine practices in Croatia and Slovenia * Aged 18 or older * Current smokers * Indicate a desire to stop smoking and to use pharmacotherapy. Exclusion Criteria: * Mental illness who cannot provide informed consent for the study * Pregna...

Countries:CroatiaSlovenia
Unlock Eligibility Criteria